NASDAQ: ANIK | Healthcare / Biotechnology / USA |
21.74 | -1.26 | -5.48% | Vol 122.00K | 1Y Perf -43.11% |
Aug 11th, 2022 16:00 DELAYED |
BID | 15.80 | ASK | 34.81 | ||
Open | 23.07 | Previous Close | 23.00 | ||
Pre-Market | - | After-Market | 21.74 | ||
- - | - -% |
Target Price | 29.00 | Analyst Rating | Hold 3.00 | |
Potential % | 33.39 | Finscreener Ranking | ★★★★+ 55.98 | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★★★ 55.80 | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★★★ 52.30 | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 6.92 | Earnings Rating | Strong Sell | |
Market Cap | 317.38M | Earnings Date | 3rd Aug 2022 | |
Alpha | -0.01 | Standard Deviation | 0.13 | |
Beta | 1.02 |
Today's Price Range 21.6323.07 | 52W Range 19.9545.81 | 5 Year PE Ratio Range -19.1059.20 |
Summary:
Sell
Technical Indicators: | Sell |
Moving Averages: | Strong Sell |
Performance | |||
---|---|---|---|
1 Week | -4.14% | ||
1 Month | -3.85% | ||
3 Months | -0.46% | ||
6 Months | -28.27% | ||
1 Year | -43.11% | ||
3 Years | -61.33% | ||
5 Years | -57.97% | ||
10 Years | 48.29% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 0.71 | |||
ROE last 12 Months | -0.60 | |||
ROA (5Y Avg) | 0.53 | |||
ROA last 12 Months | -0.48 | |||
ROC (5Y Avg) | 3.97 | |||
ROC last 12 Months | -0.54 | |||
Return on invested Capital Q | -0.95 | |||
Return on invested Capital Y | -1.87 | |||
Assets Turnover | 0.30 | |||
Receivables Turnover | 4.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-210.70 | ||||
1.18 | ||||
2.88 | ||||
37.90 | ||||
419.30 | ||||
0.61 | ||||
1.71 | ||||
19.65 | ||||
267.27M | ||||
Forward PE | -58.15 | |||
PEG | -7.84 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
4.40 | ||||
6.10 | ||||
0.06 | ||||
0.07 | ||||
- | ||||
Leverage Ratio | 1.20 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
55.80 | ||||
-12.30 | ||||
-2.70 | ||||
9.30 | ||||
-6.78 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
112.05M | ||||
7.70 | ||||
10.38 | ||||
6.80 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.19 | -0.12 | 36.84 |
Q01 2022 | -0.24 | -0.11 | 54.17 |
Q04 2021 | - | -0.23 | - |
Q03 2021 | 0.08 | 0.05 | -37.50 |
Q02 2021 | 0.04 | 0.09 | 125.00 |
Q01 2021 | 0.01 | 0.06 | 500.00 |
Q04 2020 | 0.11 | 0.12 | 9.09 |
Q03 2020 | 0.13 | -0.45 | -446.15 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.19 | -46.15 | Negative |
9/2022 QR | -0.15 | -66.67 | Negative |
12/2022 FY | -0.55 | 20.29 | Positive |
12/2023 FY | -0.39 | -34.48 | Negative |
Next Report Date | - |
Estimated EPS Next Report | -0.19 |
Estimates Count | 1 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 122.00K |
Shares Outstanding | 14.60K |
Shares Float | 10.55M |
Trades Count | 2.42K |
Dollar Volume | 2.71M |
Avg. Volume | 91.31K |
Avg. Weekly Volume | 104.21K |
Avg. Monthly Volume | 69.28K |
Avg. Quarterly Volume | 100.45K |
Anika Therapeutics Inc. (NASDAQ: ANIK) stock closed at 21.74 per share at the end of the most recent trading day (a -5.48% change compared to the prior day closing price) with a volume of 122.00K shares and market capitalization of 317.38M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Anika Therapeutics Inc. CEO is Cheryl R. Blanchard.
The one-year performance of Anika Therapeutics Inc. stock is -43.11%, while year-to-date (YTD) performance is -39.32%. ANIK stock has a five-year performance of -57.97%. Its 52-week range is between 19.9508 and 45.81, which gives ANIK stock a 52-week price range ratio of 6.92%
Anika Therapeutics Inc. currently has a PE ratio of -210.70, a price-to-book (PB) ratio of 1.18, a price-to-sale (PS) ratio of 2.88, a price to cashflow ratio of 37.90, a PEG ratio of 2.32, a ROA of -0.48%, a ROC of -0.54% and a ROE of -0.60%. The company’s profit margin is -6.78%, its EBITDA margin is -2.70%, and its revenue ttm is $112.05 Million , which makes it $7.70 revenue per share.
Of the last four earnings reports from Anika Therapeutics Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.19 for the next earnings report. Anika Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Anika Therapeutics Inc. is Hold (3), with a target price of $29, which is +33.39% compared to the current price. The earnings rating for Anika Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Anika Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Anika Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.38, ATR14 : 1.01, CCI20 : -133.31, Chaikin Money Flow : -0.23, MACD : 0.07, Money Flow Index : 40.27, ROC : -5.93, RSI : 39.97, STOCH (14,3) : 3.08, STOCH RSI : 0.00, UO : 36.86, Williams %R : -96.92), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Anika Therapeutics Inc. in the last 12-months were: Cheryl R. Blanchard (Buy at a value of $207 143), Cheryl R. Blanchard (Option Excercise at a value of $0), David Colleran (Buy at a value of $72 033), David Colleran (Option Excercise at a value of $0), Jeffery Scott Thompson (Buy at a value of $49 318), Michael L. Levitz (Buy at a value of $129 715), Michael L. Levitz (Option Excercise at a value of $0), Thomas Finnerty (Option Excercise at a value of $0)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Hold | Hold | Hold |
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.
CEO: Cheryl R. Blanchard
Telephone: +1 781 457-9000
Address: 32 Wiggins Avenue, Bedford 01730, MA, US
Number of employees: 154
Thu, 04 Aug 2022 13:25 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Anika Therapeutics (ANIK) and Galecto (GLTO)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.